nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP1A1—head and neck cancer	0.798	1	CbGaD
Dexmedetomidine—CYP2D6—Hydroxyurea—head and neck cancer	0.0484	0.55	CbGbCtD
Dexmedetomidine—CYP1A2—Fluorouracil—head and neck cancer	0.0224	0.255	CbGbCtD
Dexmedetomidine—CYP2D6—Vinblastine—head and neck cancer	0.0171	0.195	CbGbCtD
Dexmedetomidine—Septic shock—Fluorouracil—head and neck cancer	0.00393	0.0403	CcSEcCtD
Dexmedetomidine—Acute respiratory distress syndrome—Docetaxel—head and neck cancer	0.00328	0.0337	CcSEcCtD
Dexmedetomidine—Photopsia—Docetaxel—head and neck cancer	0.00269	0.0276	CcSEcCtD
Dexmedetomidine—Hypomagnesaemia—Hydroxyurea—head and neck cancer	0.00259	0.0266	CcSEcCtD
Dexmedetomidine—Neuritis—Vinblastine—head and neck cancer	0.00242	0.0248	CcSEcCtD
Dexmedetomidine—Sinus tachycardia—Docetaxel—head and neck cancer	0.00212	0.0218	CcSEcCtD
Dexmedetomidine—Blood urea increased—Hydroxyurea—head and neck cancer	0.00156	0.016	CcSEcCtD
Dexmedetomidine—Myocardial ischaemia—Fluorouracil—head and neck cancer	0.00148	0.0151	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Hydroxyurea—head and neck cancer	0.00147	0.0151	CcSEcCtD
Dexmedetomidine—Speech disorder—Fluorouracil—head and neck cancer	0.00138	0.0142	CcSEcCtD
Dexmedetomidine—Supraventricular tachycardia—Docetaxel—head and neck cancer	0.00131	0.0134	CcSEcCtD
Dexmedetomidine—Renal failure acute—Hydroxyurea—head and neck cancer	0.0013	0.0133	CcSEcCtD
Dexmedetomidine—Pharyngolaryngeal pain—Docetaxel—head and neck cancer	0.00127	0.013	CcSEcCtD
Dexmedetomidine—Leukocytosis—Fluorouracil—head and neck cancer	0.00126	0.013	CcSEcCtD
Dexmedetomidine—Laryngeal pain—Docetaxel—head and neck cancer	0.00126	0.0129	CcSEcCtD
Dexmedetomidine—Haemoglobin decreased—Docetaxel—head and neck cancer	0.00124	0.0128	CcSEcCtD
Dexmedetomidine—Neuralgia—Docetaxel—head and neck cancer	0.00123	0.0126	CcSEcCtD
Dexmedetomidine—Neuritis—Docetaxel—head and neck cancer	0.00115	0.0118	CcSEcCtD
Dexmedetomidine—Pleural effusion—Docetaxel—head and neck cancer	0.00112	0.0115	CcSEcCtD
Dexmedetomidine—Myocardial ischaemia—Docetaxel—head and neck cancer	0.00106	0.0109	CcSEcCtD
Dexmedetomidine—Rigors—Docetaxel—head and neck cancer	0.00105	0.0108	CcSEcCtD
Dexmedetomidine—Sepsis—Fluorouracil—head and neck cancer	0.00103	0.0106	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Vinblastine—head and neck cancer	0.000996	0.0102	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Vinblastine—head and neck cancer	0.000991	0.0102	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Vinblastine—head and neck cancer	0.000991	0.0102	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.000941	0.00966	CcSEcCtD
Dexmedetomidine—Oliguria—Docetaxel—head and neck cancer	0.000929	0.00953	CcSEcCtD
Dexmedetomidine—Haemoglobin—Vinblastine—head and neck cancer	0.000912	0.00936	CcSEcCtD
Dexmedetomidine—Haemorrhage—Vinblastine—head and neck cancer	0.000907	0.00931	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.000903	0.00927	CcSEcCtD
Dexmedetomidine—Respiratory failure—Docetaxel—head and neck cancer	0.000872	0.00895	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.000856	0.00878	CcSEcCtD
Dexmedetomidine—Haemoglobin—Hydroxyurea—head and neck cancer	0.000832	0.00853	CcSEcCtD
Dexmedetomidine—Haemorrhage—Hydroxyurea—head and neck cancer	0.000827	0.00849	CcSEcCtD
Dexmedetomidine—Hallucination—Hydroxyurea—head and neck cancer	0.000823	0.00845	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Fluorouracil—head and neck cancer	0.000818	0.0084	CcSEcCtD
Dexmedetomidine—Fluid retention—Docetaxel—head and neck cancer	0.000813	0.00834	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Docetaxel—head and neck cancer	0.000762	0.00782	CcSEcCtD
Dexmedetomidine—Angiopathy—Hydroxyurea—head and neck cancer	0.000751	0.0077	CcSEcCtD
Dexmedetomidine—Sepsis—Docetaxel—head and neck cancer	0.000743	0.00762	CcSEcCtD
Dexmedetomidine—Chills—Hydroxyurea—head and neck cancer	0.000742	0.00762	CcSEcCtD
Dexmedetomidine—Anaemia—Vinblastine—head and neck cancer	0.00073	0.00749	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000714	0.00733	CcSEcCtD
Dexmedetomidine—Convulsion—Vinblastine—head and neck cancer	0.000684	0.00702	CcSEcCtD
Dexmedetomidine—Hypertension—Vinblastine—head and neck cancer	0.000682	0.007	CcSEcCtD
Dexmedetomidine—Pneumonia—Fluorouracil—head and neck cancer	0.000667	0.00685	CcSEcCtD
Dexmedetomidine—Anaemia—Hydroxyurea—head and neck cancer	0.000666	0.00683	CcSEcCtD
Dexmedetomidine—Atrial fibrillation—Docetaxel—head and neck cancer	0.000656	0.00673	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000654	0.00671	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.00065	0.00667	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Fluorouracil—head and neck cancer	0.00065	0.00667	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Fluorouracil—head and neck cancer	0.000645	0.00662	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Vinblastine—head and neck cancer	0.000631	0.00648	CcSEcCtD
Dexmedetomidine—Convulsion—Hydroxyurea—head and neck cancer	0.000624	0.0064	CcSEcCtD
Dexmedetomidine—Haemoglobin—Fluorouracil—head and neck cancer	0.000599	0.00614	CcSEcCtD
Dexmedetomidine—Haemorrhage—Fluorouracil—head and neck cancer	0.000595	0.00611	CcSEcCtD
Dexmedetomidine—Infection—Hydroxyurea—head and neck cancer	0.000584	0.00599	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000575	0.00591	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000559	0.00574	CcSEcCtD
Dexmedetomidine—Constipation—Vinblastine—head and neck cancer	0.000551	0.00566	CcSEcCtD
Dexmedetomidine—Pain—Vinblastine—head and neck cancer	0.000551	0.00566	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000548	0.00562	CcSEcCtD
Dexmedetomidine—Arrhythmia—Fluorouracil—head and neck cancer	0.000532	0.00546	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Vinblastine—head and neck cancer	0.000531	0.00545	CcSEcCtD
Dexmedetomidine—Bronchospasm—Docetaxel—head and neck cancer	0.000528	0.00542	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000527	0.00541	CcSEcCtD
Dexmedetomidine—Dyspnoea—Hydroxyurea—head and neck cancer	0.000524	0.00538	CcSEcCtD
Dexmedetomidine—Somnolence—Hydroxyurea—head and neck cancer	0.000523	0.00536	CcSEcCtD
Dexmedetomidine—Abdominal pain—Vinblastine—head and neck cancer	0.000509	0.00523	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000507	0.00521	CcSEcCtD
Dexmedetomidine—Constipation—Hydroxyurea—head and neck cancer	0.000503	0.00516	CcSEcCtD
Dexmedetomidine—Pain—Hydroxyurea—head and neck cancer	0.000503	0.00516	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000484	0.00497	CcSEcCtD
Dexmedetomidine—Pneumonia—Docetaxel—head and neck cancer	0.000482	0.00494	CcSEcCtD
Dexmedetomidine—Anaemia—Fluorouracil—head and neck cancer	0.000479	0.00492	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000472	0.00484	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Docetaxel—head and neck cancer	0.000469	0.00482	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000469	0.00482	CcSEcCtD
Dexmedetomidine—Body temperature increased—Hydroxyurea—head and neck cancer	0.000465	0.00477	CcSEcCtD
Dexmedetomidine—Convulsion—Fluorouracil—head and neck cancer	0.000449	0.00461	CcSEcCtD
Dexmedetomidine—Diarrhoea—Vinblastine—head and neck cancer	0.000441	0.00453	CcSEcCtD
Dexmedetomidine—Haemoglobin—Docetaxel—head and neck cancer	0.000432	0.00443	CcSEcCtD
Dexmedetomidine—Haemorrhage—Docetaxel—head and neck cancer	0.00043	0.00441	CcSEcCtD
Dexmedetomidine—Confusional state—Fluorouracil—head and neck cancer	0.000427	0.00438	CcSEcCtD
Dexmedetomidine—Dizziness—Vinblastine—head and neck cancer	0.000426	0.00437	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Docetaxel—head and neck cancer	0.000423	0.00435	CcSEcCtD
Dexmedetomidine—Infection—Fluorouracil—head and neck cancer	0.00042	0.00431	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000414	0.00425	CcSEcCtD
Dexmedetomidine—Visual impairment—Docetaxel—head and neck cancer	0.000414	0.00425	CcSEcCtD
Dexmedetomidine—Tachycardia—Fluorouracil—head and neck cancer	0.000413	0.00424	CcSEcCtD
Dexmedetomidine—Vomiting—Vinblastine—head and neck cancer	0.00041	0.00421	CcSEcCtD
Dexmedetomidine—Headache—Vinblastine—head and neck cancer	0.000404	0.00414	CcSEcCtD
Dexmedetomidine—Diarrhoea—Hydroxyurea—head and neck cancer	0.000402	0.00413	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Docetaxel—head and neck cancer	0.000399	0.00409	CcSEcCtD
Dexmedetomidine—Hypotension—Fluorouracil—head and neck cancer	0.000395	0.00406	CcSEcCtD
Dexmedetomidine—Angiopathy—Docetaxel—head and neck cancer	0.00039	0.004	CcSEcCtD
Dexmedetomidine—Dizziness—Hydroxyurea—head and neck cancer	0.000389	0.00399	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Docetaxel—head and neck cancer	0.000387	0.00398	CcSEcCtD
Dexmedetomidine—Chills—Docetaxel—head and neck cancer	0.000386	0.00396	CcSEcCtD
Dexmedetomidine—Arrhythmia—Docetaxel—head and neck cancer	0.000384	0.00394	CcSEcCtD
Dexmedetomidine—Nausea—Vinblastine—head and neck cancer	0.000383	0.00393	CcSEcCtD
Dexmedetomidine—Dyspnoea—Fluorouracil—head and neck cancer	0.000377	0.00387	CcSEcCtD
Dexmedetomidine—Mental disorder—Docetaxel—head and neck cancer	0.000377	0.00386	CcSEcCtD
Dexmedetomidine—Somnolence—Fluorouracil—head and neck cancer	0.000376	0.00386	CcSEcCtD
Dexmedetomidine—Malnutrition—Docetaxel—head and neck cancer	0.000374	0.00384	CcSEcCtD
Dexmedetomidine—Vomiting—Hydroxyurea—head and neck cancer	0.000374	0.00384	CcSEcCtD
Dexmedetomidine—Rash—Hydroxyurea—head and neck cancer	0.000371	0.0038	CcSEcCtD
Dexmedetomidine—Dermatitis—Hydroxyurea—head and neck cancer	0.00037	0.0038	CcSEcCtD
Dexmedetomidine—Headache—Hydroxyurea—head and neck cancer	0.000368	0.00378	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000365	0.00375	CcSEcCtD
Dexmedetomidine—Pain—Fluorouracil—head and neck cancer	0.000362	0.00371	CcSEcCtD
Dexmedetomidine—Nausea—Hydroxyurea—head and neck cancer	0.000349	0.00358	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Fluorouracil—head and neck cancer	0.000349	0.00358	CcSEcCtD
Dexmedetomidine—Anaemia—Docetaxel—head and neck cancer	0.000346	0.00355	CcSEcCtD
Dexmedetomidine—Body temperature increased—Fluorouracil—head and neck cancer	0.000334	0.00343	CcSEcCtD
Dexmedetomidine—Convulsion—Docetaxel—head and neck cancer	0.000324	0.00333	CcSEcCtD
Dexmedetomidine—Hypertension—Docetaxel—head and neck cancer	0.000323	0.00332	CcSEcCtD
Dexmedetomidine—Dry mouth—Docetaxel—head and neck cancer	0.000312	0.0032	CcSEcCtD
Dexmedetomidine—Confusional state—Docetaxel—head and neck cancer	0.000308	0.00316	CcSEcCtD
Dexmedetomidine—Infection—Docetaxel—head and neck cancer	0.000303	0.00311	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Docetaxel—head and neck cancer	0.000299	0.00307	CcSEcCtD
Dexmedetomidine—Tachycardia—Docetaxel—head and neck cancer	0.000298	0.00306	CcSEcCtD
Dexmedetomidine—Diarrhoea—Fluorouracil—head and neck cancer	0.000289	0.00297	CcSEcCtD
Dexmedetomidine—Hypotension—Docetaxel—head and neck cancer	0.000285	0.00293	CcSEcCtD
Dexmedetomidine—Dizziness—Fluorouracil—head and neck cancer	0.00028	0.00287	CcSEcCtD
Dexmedetomidine—Dyspnoea—Docetaxel—head and neck cancer	0.000272	0.00279	CcSEcCtD
Dexmedetomidine—Somnolence—Docetaxel—head and neck cancer	0.000271	0.00279	CcSEcCtD
Dexmedetomidine—Vomiting—Fluorouracil—head and neck cancer	0.000269	0.00276	CcSEcCtD
Dexmedetomidine—Rash—Fluorouracil—head and neck cancer	0.000267	0.00274	CcSEcCtD
Dexmedetomidine—Dermatitis—Fluorouracil—head and neck cancer	0.000267	0.00274	CcSEcCtD
Dexmedetomidine—Headache—Fluorouracil—head and neck cancer	0.000265	0.00272	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000264	0.00271	CcSEcCtD
Dexmedetomidine—Pain—Docetaxel—head and neck cancer	0.000261	0.00268	CcSEcCtD
Dexmedetomidine—Constipation—Docetaxel—head and neck cancer	0.000261	0.00268	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Docetaxel—head and neck cancer	0.000252	0.00258	CcSEcCtD
Dexmedetomidine—Nausea—Fluorouracil—head and neck cancer	0.000251	0.00258	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00025	0.00256	CcSEcCtD
Dexmedetomidine—Abdominal pain—Docetaxel—head and neck cancer	0.000241	0.00248	CcSEcCtD
Dexmedetomidine—Body temperature increased—Docetaxel—head and neck cancer	0.000241	0.00248	CcSEcCtD
Dexmedetomidine—Diarrhoea—Docetaxel—head and neck cancer	0.000209	0.00214	CcSEcCtD
Dexmedetomidine—Dizziness—Docetaxel—head and neck cancer	0.000202	0.00207	CcSEcCtD
Dexmedetomidine—Vomiting—Docetaxel—head and neck cancer	0.000194	0.00199	CcSEcCtD
Dexmedetomidine—Rash—Docetaxel—head and neck cancer	0.000193	0.00198	CcSEcCtD
Dexmedetomidine—Dermatitis—Docetaxel—head and neck cancer	0.000192	0.00197	CcSEcCtD
Dexmedetomidine—Headache—Docetaxel—head and neck cancer	0.000191	0.00196	CcSEcCtD
Dexmedetomidine—Nausea—Docetaxel—head and neck cancer	0.000181	0.00186	CcSEcCtD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	2.12e-05	0.0013	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	2.11e-05	0.0013	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Platelet activation, signaling and aggregation—MAPK3—head and neck cancer	2.1e-05	0.0013	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KISS1—head and neck cancer	2.08e-05	0.00128	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KISS1—head and neck cancer	2.05e-05	0.00126	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—GRP—head and neck cancer	2.03e-05	0.00125	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	2.01e-05	0.00124	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	2.01e-05	0.00124	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	2e-05	0.00123	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT6—head and neck cancer	1.98e-05	0.00122	CbGpPWpGaD
Dexmedetomidine—ADRA1B—G alpha (q) signalling events—PIK3CA—head and neck cancer	1.95e-05	0.0012	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	1.95e-05	0.0012	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	1.86e-05	0.00115	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—DPYD—head and neck cancer	1.86e-05	0.00115	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—GRP—head and neck cancer	1.84e-05	0.00113	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—head and neck cancer	1.81e-05	0.00111	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT6—head and neck cancer	1.78e-05	0.0011	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	1.78e-05	0.00109	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—YAP1—head and neck cancer	1.76e-05	0.00109	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—YAP1—head and neck cancer	1.75e-05	0.00108	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	1.75e-05	0.00108	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	1.74e-05	0.00107	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—NAT2—head and neck cancer	1.72e-05	0.00106	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—GRP—head and neck cancer	1.72e-05	0.00106	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—MAPK3—head and neck cancer	1.71e-05	0.00105	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KISS1—head and neck cancer	1.69e-05	0.00104	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—GRP—head and neck cancer	1.69e-05	0.00104	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT6—head and neck cancer	1.67e-05	0.00103	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT6—head and neck cancer	1.64e-05	0.00101	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	1.63e-05	0.001	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	1.62e-05	0.000997	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.58e-05	0.000975	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—NAT2—head and neck cancer	1.58e-05	0.000974	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—YAP1—head and neck cancer	1.58e-05	0.000973	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	1.52e-05	0.000936	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—DPYD—head and neck cancer	1.51e-05	0.00093	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—NAT2—head and neck cancer	1.49e-05	0.000919	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—YAP1—head and neck cancer	1.47e-05	0.000909	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—YAP1—head and neck cancer	1.45e-05	0.000894	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—IL2—head and neck cancer	1.44e-05	0.00089	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—YAP1—head and neck cancer	1.43e-05	0.000883	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	1.42e-05	0.000875	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	1.41e-05	0.00087	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GRP—head and neck cancer	1.39e-05	0.000859	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—DPYD—head and neck cancer	1.39e-05	0.000854	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT6—head and neck cancer	1.35e-05	0.000834	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—IL2—head and neck cancer	1.35e-05	0.000831	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—YAP1—head and neck cancer	1.32e-05	0.000811	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—DPYD—head and neck cancer	1.31e-05	0.000805	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—YAP1—head and neck cancer	1.24e-05	0.000764	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—VEGFA—head and neck cancer	1.23e-05	0.000756	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—YAP1—head and neck cancer	1.2e-05	0.000738	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—MAPK3—head and neck cancer	1.16e-05	0.000716	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	1.15e-05	0.00071	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—VEGFA—head and neck cancer	1.15e-05	0.000707	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—NAT2—head and neck cancer	1.12e-05	0.000691	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—MAPK1—head and neck cancer	1.1e-05	0.000681	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—IL2—head and neck cancer	1.1e-05	0.000675	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—MAPK3—head and neck cancer	1.08e-05	0.000668	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—TYMS—head and neck cancer	1.06e-05	0.000653	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—GSTM1—head and neck cancer	1.05e-05	0.000645	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—MAPK1—head and neck cancer	1.03e-05	0.000636	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—IL2—head and neck cancer	1.01e-05	0.000623	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.01e-05	0.000622	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—GPX1—head and neck cancer	1e-05	0.000618	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	9.99e-06	0.000616	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CYP1A1—head and neck cancer	9.92e-06	0.000612	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—DPYD—head and neck cancer	9.84e-06	0.000606	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—PIK3CA—head and neck cancer	9.59e-06	0.000591	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NAT2—head and neck cancer	9.5e-06	0.000586	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—YAP1—head and neck cancer	9.33e-06	0.000575	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	9.32e-06	0.000574	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—VEGFA—head and neck cancer	9.31e-06	0.000574	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—TP53—head and neck cancer	9.27e-06	0.000572	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL2—head and neck cancer	9.18e-06	0.000566	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—IL2—head and neck cancer	9.13e-06	0.000562	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—PIK3CA—head and neck cancer	8.95e-06	0.000552	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—HRAS—head and neck cancer	8.87e-06	0.000547	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—MAPK3—head and neck cancer	8.81e-06	0.000543	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—TP53—head and neck cancer	8.66e-06	0.000534	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—TYMS—head and neck cancer	8.6e-06	0.00053	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—IL2—head and neck cancer	8.52e-06	0.000525	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GSTM1—head and neck cancer	8.5e-06	0.000524	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—IL2—head and neck cancer	8.39e-06	0.000517	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—MAPK1—head and neck cancer	8.38e-06	0.000517	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—DPYD—head and neck cancer	8.33e-06	0.000514	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL2—head and neck cancer	8.29e-06	0.000511	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—HRAS—head and neck cancer	8.28e-06	0.000511	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GPX1—head and neck cancer	8.14e-06	0.000502	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	8.13e-06	0.000501	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CYP1A1—head and neck cancer	8.06e-06	0.000497	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—YAP1—head and neck cancer	7.91e-06	0.000487	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—TYMS—head and neck cancer	7.9e-06	0.000487	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NOTCH1—head and neck cancer	7.88e-06	0.000486	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—AKT1—head and neck cancer	7.83e-06	0.000483	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GSTM1—head and neck cancer	7.81e-06	0.000481	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL2—head and neck cancer	7.74e-06	0.000477	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL2—head and neck cancer	7.62e-06	0.00047	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GPX1—head and neck cancer	7.48e-06	0.000461	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—TYMS—head and neck cancer	7.45e-06	0.000459	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CYP1A1—head and neck cancer	7.4e-06	0.000456	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—MAPK3—head and neck cancer	7.38e-06	0.000455	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GSTM1—head and neck cancer	7.36e-06	0.000454	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—AKT1—head and neck cancer	7.31e-06	0.000451	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—PIK3CA—head and neck cancer	7.27e-06	0.000448	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NOTCH1—head and neck cancer	7.11e-06	0.000438	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GPX1—head and neck cancer	7.05e-06	0.000434	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—TP53—head and neck cancer	7.04e-06	0.000434	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—MAPK1—head and neck cancer	7.02e-06	0.000433	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—EGFR—head and neck cancer	7.02e-06	0.000433	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—IL2—head and neck cancer	6.92e-06	0.000427	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—HRAS—head and neck cancer	6.73e-06	0.000415	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—PIK3CA—head and neck cancer	6.71e-06	0.000414	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—MAPK3—head and neck cancer	6.66e-06	0.000411	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NOTCH1—head and neck cancer	6.65e-06	0.00041	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NOTCH1—head and neck cancer	6.54e-06	0.000403	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—MAPK1—head and neck cancer	6.34e-06	0.000391	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—EGFR—head and neck cancer	6.34e-06	0.000391	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL2—head and neck cancer	6.29e-06	0.000388	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—MAPK3—head and neck cancer	6.22e-06	0.000384	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—MAPK3—head and neck cancer	6.13e-06	0.000378	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—PIK3CA—head and neck cancer	6.09e-06	0.000376	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—PIK3CA—head and neck cancer	6.06e-06	0.000373	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—AKT1—head and neck cancer	5.94e-06	0.000366	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	5.94e-06	0.000366	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—MAPK1—head and neck cancer	5.92e-06	0.000365	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—EGFR—head and neck cancer	5.92e-06	0.000365	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTGS2—head and neck cancer	5.9e-06	0.000364	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—MAPK1—head and neck cancer	5.83e-06	0.000359	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—EGFR—head and neck cancer	5.83e-06	0.000359	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	5.73e-06	0.000353	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—PIK3CA—head and neck cancer	5.66e-06	0.000349	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—HRAS—head and neck cancer	5.64e-06	0.000347	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—TYMS—head and neck cancer	5.6e-06	0.000345	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—PIK3CA—head and neck cancer	5.57e-06	0.000343	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTM1—head and neck cancer	5.54e-06	0.000341	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PIK3CA—head and neck cancer	5.5e-06	0.000339	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—AKT1—head and neck cancer	5.48e-06	0.000338	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL2—head and neck cancer	5.42e-06	0.000334	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOTCH1—head and neck cancer	5.4e-06	0.000333	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GPX1—head and neck cancer	5.31e-06	0.000327	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCND1—head and neck cancer	5.29e-06	0.000326	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP1A1—head and neck cancer	5.25e-06	0.000324	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	5.18e-06	0.000319	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTEN—head and neck cancer	5.15e-06	0.000317	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PIK3CA—head and neck cancer	5.14e-06	0.000317	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PTEN—head and neck cancer	5.1e-06	0.000314	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—HRAS—head and neck cancer	5.09e-06	0.000314	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PIK3CA—head and neck cancer	5.06e-06	0.000312	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—MAPK3—head and neck cancer	5.06e-06	0.000312	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—AKT1—head and neck cancer	4.98e-06	0.000307	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—AKT1—head and neck cancer	4.95e-06	0.000305	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL2—head and neck cancer	4.9e-06	0.000302	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—MAPK1—head and neck cancer	4.81e-06	0.000296	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—head and neck cancer	4.81e-06	0.000296	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTGS2—head and neck cancer	4.79e-06	0.000295	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCND1—head and neck cancer	4.77e-06	0.000294	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—HRAS—head and neck cancer	4.75e-06	0.000293	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—TYMS—head and neck cancer	4.75e-06	0.000293	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTM1—head and neck cancer	4.69e-06	0.000289	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—HRAS—head and neck cancer	4.68e-06	0.000288	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—AKT1—head and neck cancer	4.62e-06	0.000285	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—head and neck cancer	4.61e-06	0.000284	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTEN—head and neck cancer	4.61e-06	0.000284	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CA—head and neck cancer	4.6e-06	0.000283	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL2—head and neck cancer	4.57e-06	0.000282	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT3—head and neck cancer	4.56e-06	0.000281	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—AKT1—head and neck cancer	4.55e-06	0.00028	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL2—head and neck cancer	4.5e-06	0.000277	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GPX1—head and neck cancer	4.49e-06	0.000277	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—AKT1—head and neck cancer	4.49e-06	0.000277	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCND1—head and neck cancer	4.46e-06	0.000275	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP1A1—head and neck cancer	4.45e-06	0.000274	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTGS2—head and neck cancer	4.4e-06	0.000271	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCND1—head and neck cancer	4.39e-06	0.00027	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK3—head and neck cancer	4.36e-06	0.000269	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTEN—head and neck cancer	4.3e-06	0.000265	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTEN—head and neck cancer	4.23e-06	0.000261	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—AKT1—head and neck cancer	4.2e-06	0.000259	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTEN—head and neck cancer	4.18e-06	0.000258	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CA—head and neck cancer	4.17e-06	0.000257	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—head and neck cancer	4.16e-06	0.000256	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTGS2—head and neck cancer	4.15e-06	0.000256	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK1—head and neck cancer	4.15e-06	0.000256	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—head and neck cancer	4.15e-06	0.000256	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—AKT1—head and neck cancer	4.13e-06	0.000255	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT3—head and neck cancer	4.12e-06	0.000254	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK3—head and neck cancer	3.94e-06	0.000243	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—head and neck cancer	3.89e-06	0.00024	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—HRAS—head and neck cancer	3.86e-06	0.000238	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT3—head and neck cancer	3.85e-06	0.000237	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTEN—head and neck cancer	3.84e-06	0.000237	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—head and neck cancer	3.82e-06	0.000236	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT3—head and neck cancer	3.79e-06	0.000233	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—AKT1—head and neck cancer	3.75e-06	0.000231	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK1—head and neck cancer	3.74e-06	0.000231	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—head and neck cancer	3.74e-06	0.000231	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL2—head and neck cancer	3.71e-06	0.000229	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK3—head and neck cancer	3.68e-06	0.000227	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	3.65e-06	0.000225	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CA—head and neck cancer	3.63e-06	0.000224	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCND1—head and neck cancer	3.62e-06	0.000223	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTEN—head and neck cancer	3.62e-06	0.000223	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK3—head and neck cancer	3.62e-06	0.000223	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CA—head and neck cancer	3.6e-06	0.000222	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK1—head and neck cancer	3.5e-06	0.000216	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—head and neck cancer	3.5e-06	0.000216	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTEN—head and neck cancer	3.49e-06	0.000215	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—head and neck cancer	3.48e-06	0.000215	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK1—head and neck cancer	3.44e-06	0.000212	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—head and neck cancer	3.44e-06	0.000212	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—AKT1—head and neck cancer	3.41e-06	0.00021	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HRAS—head and neck cancer	3.33e-06	0.000205	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CA—head and neck cancer	3.25e-06	0.0002	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—head and neck cancer	3.16e-06	0.000195	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—head and neck cancer	3.14e-06	0.000194	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT3—head and neck cancer	3.13e-06	0.000193	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS2—head and neck cancer	3.12e-06	0.000192	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CA—head and neck cancer	3.04e-06	0.000187	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HRAS—head and neck cancer	3.01e-06	0.000185	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CA—head and neck cancer	2.99e-06	0.000184	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK3—head and neck cancer	2.99e-06	0.000184	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AKT1—head and neck cancer	2.97e-06	0.000183	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CA—head and neck cancer	2.95e-06	0.000182	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKT1—head and neck cancer	2.94e-06	0.000181	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—head and neck cancer	2.94e-06	0.000181	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—head and neck cancer	2.89e-06	0.000178	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK1—head and neck cancer	2.84e-06	0.000175	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—head and neck cancer	2.84e-06	0.000175	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HRAS—head and neck cancer	2.81e-06	0.000173	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HRAS—head and neck cancer	2.76e-06	0.00017	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTEN—head and neck cancer	2.72e-06	0.000168	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CA—head and neck cancer	2.71e-06	0.000167	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKT1—head and neck cancer	2.65e-06	0.000164	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS2—head and neck cancer	2.65e-06	0.000163	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CA—head and neck cancer	2.55e-06	0.000157	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKT1—head and neck cancer	2.48e-06	0.000153	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CA—head and neck cancer	2.47e-06	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKT1—head and neck cancer	2.44e-06	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AKT1—head and neck cancer	2.41e-06	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—head and neck cancer	2.39e-06	0.000147	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTEN—head and neck cancer	2.31e-06	0.000142	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HRAS—head and neck cancer	2.28e-06	0.000141	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AKT1—head and neck cancer	2.21e-06	0.000136	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AKT1—head and neck cancer	2.09e-06	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKT1—head and neck cancer	2.01e-06	0.000124	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CA—head and neck cancer	1.92e-06	0.000118	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CA—head and neck cancer	1.63e-06	0.0001	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AKT1—head and neck cancer	1.57e-06	9.67e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AKT1—head and neck cancer	1.33e-06	8.2e-05	CbGpPWpGaD
